Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARROW
NCT04932980Active, not recruiting
- Sponsor
- Berner Augenklinik
- Start
- May 2022
- Primary completion
- Jun 2027
- Modality
- scFv Fragments, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial in exudative macular degeneration comparing Aflibercept rapid treatment extension (T&E) with Brolucizumab rapid treatment extension (T&E) (2 arms). Primary endpoint: Number of injections given at 52 weeks. Started May 2022; status: active, not recruiting.
02
Drugs
afliberceptbrolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04932980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932980.